<Research>CICC Ratings, TPs on Medical Health Stocks (Table)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Source: aastocks
Stock Performance Overview: Several pharmaceutical stocks in Hong Kong, including SKB BIO-B and INNOVENT BIO, showed positive gains with notable short selling ratios, indicating varying investor sentiments and market dynamics.
Market Insights: Analysts maintain an "Outperform" rating on multiple companies like HENGRUI PHARMA and CSPC PHARMA, highlighting strong fundamentals despite some stocks experiencing price weakness.
Analyst Views on 00512
Wall Street analysts forecast 00512 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00512 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 7.900
Low
Averages
High
Current: 7.900
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
